Healthcare Industry News: Microvolt T-Wave Alternans
News Release - March 15, 2007
Data Highlighting Cambridge Heart's Non-Invasive HearTwave(R) II System to be Presented in Late Breaker at American College of Cardiology Meeting
BEDFORD, Mass.--(HSMN NewsFeed)--Cambridge Heart, Inc. (OTCBB:CAMH ), today announced results from the ALPHA (T-Wave Alternans in Patients With Heart Failure) clinical study will be featured as a late-breaker presentation during the 56th Annual Scientific Session of The American College of Cardiology being held March 24 - 27 in New Orleans. The presentation will be given at 8:30 AM CDT during a plenary session on Sunday, March 25, 2007.The ALPHA study was a multicenter prospective study designed to evaluate the independent predictive value of the measurement of Microvolt T-Wave Alternans (MTWA) utilizing Cambridge Heart's non-invasive HearTwave® II MTWA System on the combined occurrence of cardiac death and life-threatening arrhythmias in patients with non-ischemic dilated cardiomyopathy. The study was funded by Boston Scientific.
About The Non-Invasive HearTwave® II Microvolt T-Wave Alternans System
Cambridge Heart's HearTwave II Microvolt T-Wave Alternans System measures a specific and extremely subtle pattern of beat-to-beat fluctuations in a person's electrocardiogram. This pattern of fluctuations is called T-wave alternans. These tiny variations in the electrocardiogram, measured at one millionth of a volt accuracy, are measured most commonly during a sub-maximal exercise stress test in the doctor's office or hospital outpatient setting. Extensive clinical research has shown patients with a positive or non-negative Microvolt T-Wave Alternans test are at increased risk for sudden cardiac death, while those who test negative are at reduced risk.
About Cambridge Heart, Inc.
Cambridge Heart (www.cambridgeheart.com) is engaged in the development and commercialization of products for the non-invasive diagnosis of cardiac disease, particularly the identification of those at risk of sudden cardiac arrest. The Company's products incorporate its proprietary Microvolt T-Wave Alternans measurement technologies, coupled with its patented Spectral Analytic Method and ultra-sensitive disposable electrode sensors. Only Spectral Analytic Method MTWA tests are reimbursed by Medicare under its National Coverage Policy that covers patients with a wide variety of cardiac symptoms. Other major insurers in the U.S. also have coverage policies for the test. The T-Wave Alternans test is included in the Guideline for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death jointly developed by the American College of Cardiology (ACC), The American Heart Association (AHA), and the European Society of Cardiology (ESC). The Company, founded in 1990, is based in Bedford, Massachusetts, and is traded on the OTCBB under the symbol CAMH.
Statements contained in this press release are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. In some cases, we use words such as "believes", "expects", "anticipates", "plans", "estimates", "could", and similar expressions that convey uncertainty of future events or outcomes to identify these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements. Factors that may cause or contribute to such differences include customer delays in making final buying decisions, decreased demand for our products, failure to obtain funding necessary to develop or enhance our technology, adverse results in future clinical studies of our technology, failure to obtain or maintain patent protection for our technology, failure to obtain or maintain adequate levels of third-party reimbursement for use of our products and other factors identified in our most recent Annual Report on Form 10-K under "Factors Which May Affect Future Results", which is on file with the SEC and available at www.EDGAR.com. In addition, any forward-looking statements represent our estimates only as of today and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so except as may be legally necessary, even if our estimates should change.
Source: Cambridge Heart
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
